BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28394406)

  • 1. PBRM1 loss is a late event during the development of cholangiocarcinoma.
    Luchini C; Robertson SA; Hong SM; Felsenstein M; Anders RA; Pea A; Nottegar A; Veronese N; He J; Weiss MJ; Capelli P; Scarpa A; Argani P; Kapur P; Wood LD
    Histopathology; 2017 Sep; 71(3):375-382. PubMed ID: 28394406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss.
    Misumi K; Hayashi A; Shibahara J; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M
    Histopathology; 2017 Apr; 70(5):766-774. PubMed ID: 27864835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas.
    Jiao Y; Pawlik TM; Anders RA; Selaru FM; Streppel MM; Lucas DJ; Niknafs N; Guthrie VB; Maitra A; Argani P; Offerhaus GJA; Roa JC; Roberts LR; Gores GJ; Popescu I; Alexandrescu ST; Dima S; Fassan M; Simbolo M; Mafficini A; Capelli P; Lawlor RT; Ruzzenente A; Guglielmi A; Tortora G; de Braud F; Scarpa A; Jarnagin W; Klimstra D; Karchin R; Velculescu VE; Hruban RH; Vogelstein B; Kinzler KW; Papadopoulos N; Wood LD
    Nat Genet; 2013 Dec; 45(12):1470-1473. PubMed ID: 24185509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas.
    Hsu M; Sasaki M; Igarashi S; Sato Y; Nakanuma Y
    Cancer; 2013 May; 119(9):1669-74. PubMed ID: 23335286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?
    Bagante F; Ruzzenente A; Conci S; Rusev BC; Simbolo M; Campagnaro T; Pawlik TM; Luchini C; Iacono C; Scarpa A; Guglielmi A
    HPB (Oxford); 2019 Dec; 21(12):1648-1655. PubMed ID: 31122820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.
    Simbolo M; Fassan M; Ruzzenente A; Mafficini A; Wood LD; Corbo V; Melisi D; Malleo G; Vicentini C; Malpeli G; Antonello D; Sperandio N; Capelli P; Tomezzoli A; Iacono C; Lawlor RT; Bassi C; Hruban RH; Guglielmi A; Tortora G; de Braud F; Scarpa A
    Oncotarget; 2014 May; 5(9):2839-52. PubMed ID: 24867389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PBRM1 (BAF180) protein is functionally regulated by p53-induced protein degradation in renal cell carcinomas.
    Macher-Goeppinger S; Keith M; Tagscherer KE; Singer S; Winkler J; Hofmann TG; Pahernik S; Duensing S; Hohenfellner M; Kopitz J; Schirmacher P; Roth W
    J Pathol; 2015 Dec; 237(4):460-71. PubMed ID: 26178300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of ARID1A Expression Presents a Novel Pathway of Carcinogenesis in Biliary Carcinomas.
    Sasaki M; Nitta T; Sato Y; Nakanuma Y
    Am J Clin Pathol; 2016 Jun; 145(6):815-25. PubMed ID: 27334809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low expression of ARID1A correlates with poor prognosis in intrahepatic cholangiocarcinoma.
    Yang SZ; Wang AQ; Du J; Wang JT; Yu WW; Liu Q; Wu YF; Chen SG
    World J Gastroenterol; 2016 Jul; 22(25):5814-21. PubMed ID: 27433094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective study.
    Bi C; Liu M; Rong W; Wu F; Zhang Y; Lin S; Liu Y; Wu J; Wang L
    BMC Cancer; 2019 Mar; 19(1):213. PubMed ID: 30849962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.
    Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ
    Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ring finger protein 43 expression is associated with genetic alteration status and poor prognosis among patients with intrahepatic cholangiocarcinoma.
    Talabnin C; Janthavon P; Thongsom S; Suginta W; Talabnin K; Wongkham S
    Hum Pathol; 2016 Jun; 52():47-54. PubMed ID: 26980022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DMBT1 expression in biliary carcinogenesis with correlation of clinicopathological data.
    Goeppert B; Roessler S; Becker N; Zucknick M; Vogel MN; Warth A; Pathil-Warth A; Mehrabi A; Schirmacher P; Mollenhauer J; Renner M
    Histopathology; 2017 Jun; 70(7):1064-1071. PubMed ID: 28130841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTEN loss and KRAS activation cooperate in murine biliary tract malignancies.
    Marsh V; Davies EJ; Williams GT; Clarke AR
    J Pathol; 2013 Jun; 230(2):165-73. PubMed ID: 23483557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polybromo-1 (PBRM1), a SWI/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma.
    da Costa WH; Rezende M; Carneiro FC; Rocha RM; da Cunha IW; Carraro DM; Guimaraes GC; de Cassio Zequi S
    BJU Int; 2014 May; 113(5b):E157-63. PubMed ID: 24053427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: correlations with cholangiocarcinoma aggressiveness.
    Vasuri F; Rocchi L; Degiovanni A; Giunchi F; Brandi G; Treré D; Montanaro L; D'Errico-Grigioni A
    Histopathology; 2015 Jan; 66(2):244-51. PubMed ID: 25367684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of PBRM1 expression is associated with renal cell carcinoma progression.
    Pawłowski R; Mühl SM; Sulser T; Krek W; Moch H; Schraml P
    Int J Cancer; 2013 Jan; 132(2):E11-7. PubMed ID: 22949125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extensive biliary intraepithelial neoplasia (BilIN) and multifocal early intrahepatic cholangiocarcinoma in non-biliary cirrhosis.
    Rougemont AL; Genevay M; McKee TA; Gremaud M; Mentha G; Rubbia-Brandt L
    Virchows Arch; 2010 Jun; 456(6):711-7. PubMed ID: 20428886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
    Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
    Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
    Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
    J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.